Roger Stupp
Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14.
König D, Savic Prince S, Hayoz S, Zens P, Berezowska S, Jochum W, Stauffer E, Braunersreuther V, Trachsel B, Thierstein S, Mark M, Schmid S, Curioni-Fontecedro A, Addeo A, Schmitt-Opitz I, Guckenberger M, Früh M, Betticher D, Ris H, Stupp R, Rothschild S, Bubendorf L, Pless M. Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14. ESMO Open 2023; 8:101595.
11.07.2023Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14.
11.07.2023ESMO Open 2023; 8:101595
König Dietmar-Pierree, Savic Prince Spasenija, Hayoz Stefanie, Zens P, Berezowska Sabina, Jochum Wolfram, Stauffer Edouard, Braunersreuther V, Trachsel B, Thierstein Sandra, Mark Michael Thomas, Schmid Sebastian M, Curioni-Fontecedro Alessandra, Addeo Alfredo, Schmitt-Opitz Isabelle, Guckenberger Matthias, Früh Martin, Betticher Daniel C, Ris H B, Stupp Roger, Rothschild Sacha I, Bubendorf Lukas, Pless Miklos
Extended resection for potentially operable patients with stage III non-small cell lung cancer after induction treatment.
Furrer K, Weder W, Eboulet E, Betticher D, Pless M, Stupp R, Krueger T, Perentes J, Schmid R, Lardinois D, Furrer M, Früh M, Peters S, Curioni-Fontecedro A, Stahel R, Rothschild S, Hayoz S, Opitz I. Extended resection for potentially operable patients with stage III non-small cell lung cancer after induction treatment. J Thorac Cardiovasc Surg 2022; 164:1587-1602.e5.
18.04.2022Extended resection for potentially operable patients with stage III non-small cell lung cancer after induction treatment.
18.04.2022J Thorac Cardiovasc Surg 2022; 164:1587-1602.e5
Furrer Katarzyna, Weder Walter, Eboulet Eric Innocents, Betticher Daniel, Pless Miklos, Stupp Roger, Krueger Thorsten, Perentes Jean Yannis, Schmid Ralph A, Lardinois Didier, Furrer Markus, Früh Martin, Peters Solange, Curioni-Fontecedro Alessandra, Stahel Rolf A, Rothschild Sacha I, Hayoz Stefanie, Opitz Isabelle
Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01)
Früh M, Guckenberger M, Rothschild S, Lardinois D, Mach N, Mark M, Gautschi O, Thierstein S, Biaggi Rudolf C, Weder W, Stahel R, Matzinger O, Betticher D, Stupp R, Xyrafas A, Peters S, Ris H, Mirimanoff R, Ochsenbein A, Schmid R, Pless M. Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01). J Thorac Oncol 2018
26.09.2018Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01)
26.09.2018J Thorac Oncol 2018
Früh Martin, Guckenberger Matthias, Rothschild Sacha I, Lardinois Didier, Mach Nicholas, Mark Michael, Gautschi Oliver, Thierstein Sandra, Biaggi Rudolf Christine, Weder Walter, Stahel Rolf A, Matzinger Oscar, Betticher Daniel C, Stupp Roger, Xyrafas Alexandros, Peters Solange, Ris Hans Beat, Mirimanoff Rene Olivier, Ochsenbein Adrian F, Schmid Ralph, Pless Miklos
Diagnostic value of F-fluordesoxyglucose positron emission tomography for patients with brain metastasis from unknown primary site
Wolpert F, Preusser M, Kaufmann P, Reyns N, Roth P, Frauenfelder T, Dummer R, Stahel R, Stupp R, Neidert M, Regli L, Andratschke N, Leske H, Petyt G, Füreder L, Rushing E, Berghoff A, Weller M, Le Rhun E. Diagnostic value of F-fluordesoxyglucose positron emission tomography for patients with brain metastasis from unknown primary site. Eur J Cancer 2018; 96:64-72.
17.04.2018Diagnostic value of F-fluordesoxyglucose positron emission tomography for patients with brain metastasis from unknown primary site
17.04.2018Eur J Cancer 2018; 96:64-72
Wolpert Fabian, Preusser Matthias, Kaufmann Philipp Antonio, Reyns Nicolas, Roth Patrick, Frauenfelder Thomas, Dummer Reinhard, Stahel Rolf, Stupp Roger, Neidert Marian Christoph, Regli Luca, Andratschke Nicolaus, Leske Henning, Petyt Gregory, Füreder Lisa Michaela, Rushing Elisabeth, Berghoff Anna Sophie, Weller Michael, Le Rhun Emilie
ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016
Kunstfeld R, Moser E, Mountzios G, Moynihan T, Nielsen T, Ohe Y, Öberg K, Palumbo A, Peccatori F, Pfeilstöcker M, Raut C, Michielin O, Meran J, Lenz H, Lichtman S, Licitra L, Lion T, Litière S, Liu L, Loehrer P, Markham M, Markman B, Mayerhoefer M, Remick S, Robson M, Rutkowski P, Stupp R, Sullivan R, Tabernero J, Travado L, Verheij M, Voest E, Vokes E, Von Roenn J, Weber J, Wildiers H, Strasser F, Stiefel F, Salgado R, Schapira L, Schernhammer E, Schlumberger M, Schmoll H, Schnipper L, Sessa C, Shapiro C, Steele J, Sternberg C, Yarden Y, Dittrich C, Bhatia S, Bogaerts J, Buckner J, Cardoso F, Casali P, Chu E, Close J, Coiffier B, Connolly R, Coupland S, Banerjee S, Awada A, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El-Saghir N, Lotz J, Österlund P, Pavlidis N, Purkalne G, De Petris L, De Santis M, de Vries E, Hahn S, Hanna D, Herold C, Herrstedt J, Homicsko K, Jones D, Jost L, Keilholz U, Khan S, Kiss A, Grothey A, Gopalan P, Dizon D, Duff J, Duska L, Eniu A, Ernstoff M, Felip E, Fey M, Gilbert J, Girard N, Glaudemans A, Köhne C. ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. ESMO Open 2016; 1:e000097.
29.09.2016ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016
29.09.2016ESMO Open 2016; 1:e000097
Kunstfeld Rainer, Moser Elizabeth Charlotte, Mountzios Giannis, Moynihan Timothy, Nielsen Torsten, Ohe Yuichiro, Öberg Kjell, Palumbo Antonio, Peccatori Fedro Alessandro, Pfeilstöcker Michael, Raut Chandrajit, Michielin Olivier, Meran Johannes G, Lenz Heinz-Josef, Lichtman Stuart, Licitra Lisa, Lion Thomas, Litière Saskia, Liu Lifang, Loehrer Patrick J, Markham Merry Jennifer, Markman Ben, Mayerhoefer Marius, Remick Scot C, Robson Mark, Rutkowski Piotr, Stupp Roger, Sullivan Richard, Tabernero Josep, Travado Luzia, Verheij Marcel, Voest Emile, Vokes Everett, Von Roenn Jamie, Weber Jeffrey S, Wildiers Hans, Strasser Florian, Stiefel Friedrich, Salgado Roberto, Schapira Lidia, Schernhammer Eva, Schlumberger Martin, Schmoll Hans-Joachim, Schnipper Lowell, Sessa Cristiana, Shapiro Charles L, Steele Julie, Sternberg Cora N, Yarden Yosef, Dittrich Christian, Bhatia Smita, Bogaerts Jan, Buckner Jan, Cardoso Fatima, Casali Paolo, Chu Edward, Close Julia Lee, Coiffier Bertrand, Connolly Roisin, Coupland Sarah, Banerjee Susana, Awada Ahmad, Kosty Michael, Jezdic Svetlana, Pyle Doug, Berardi Rossana, Bergh Jonas, El-Saghir Nagi, Lotz Jean-Pierre, Österlund Pia, Pavlidis Nicholas, Purkalne Gunta, De Petris Luigi, De Santis Maria, de Vries Elisabeth G E, Hahn Stephen M, Hanna Diana, Herold Christian, Herrstedt Jørn, Homicsko Krisztian, Jones Dennie V, Jost Lorenz, Keilholz Ulrich, Khan Saad, Kiss Alexander, Grothey Axel, Gopalan Priya K, Dizon Don S, Duff Jennifer, Duska Linda R, Eniu Alexandru, Ernstoff Marc, Felip Enriqueta, Fey Martin F, Gilbert Jill, Girard Nicolas, Glaudemans Andor W J M, Köhne Claus-Henning
Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082)
Wick W, Golfinopoulos V, Frenel J, Campone M, Ricard D, Marosi C, Villa S, Weyerbrock A, Hopkins K, Homicsko K, Lhermitte B, Pesce G, Roth P, Stupp R, Gorlia T, Bady P, Platten M, van den Bent M, Taphoorn M, Steuve J, Brandes A, Hamou M, Wick A, Kosch M, Weller M, Hegi M. Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082). Clin Cancer Res 2016; 22:4797-4806.
03.05.2016Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082)
03.05.2016Clin Cancer Res 2016; 22:4797-4806
Wick Wolfgang, Golfinopoulos Vassilis, Frenel Jean-Sebastien, Campone Mario, Ricard Damien, Marosi Christine, Villa Salvador, Weyerbrock Astrid, Hopkins Kirsten, Homicsko Krisztian, Lhermitte Benoit, Pesce Gianfranco, Roth Patrick, Stupp Roger, Gorlia Thierry, Bady Pierre, Platten Michael, van den Bent Martin J, Taphoorn Martin J B, Steuve Jonathan, Brandes Alba A, Hamou Marie-France, Wick Antje, Kosch Markus, Weller Michael, Hegi Monika E
Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial
Pless M, Bijelovic M, Ochsenbein A, Meier U, Mamot C, Rauch D, Gautschi O, Betticher D, Mirimanoff R, Peters S, Roth A, Zippelius A, Stupp R, Ris H, Stahel R, Weder W, Thierstein S, Gerard M, Xyrafas A, Früh M, Cathomas R. Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial. Lancet 2015; 386:1049-56.
11.08.2015Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial
11.08.2015Lancet 2015; 386:1049-56
Pless Miklos, Bijelovic Milorad, Ochsenbein Adrian, Meier Urs R, Mamot Christoph, Rauch Daniel, Gautschi Oliver, Betticher Daniel C, Mirimanoff René-Olivier, Peters Solange, Roth Arnaud, Zippelius Alfred, Stupp Roger, Ris Hans-Beat, Stahel Rolf A, Weder Walter, Thierstein Sandra, Gerard Marie-Aline, Xyrafas Alexandros, Früh Martin, Cathomas Richard
Clinical management and outcome of histologically verified adult brainstem gliomas in Switzerland: a retrospective analysis of 21 patients
Hundsberger T, Tonder M, Hottinger A, Brügge D, Roelcke U, Putora P, Stupp R, Weller M. Clinical management and outcome of histologically verified adult brainstem gliomas in Switzerland: a retrospective analysis of 21 patients. J Neurooncol 2014; 118:321-328.
16.04.2014Clinical management and outcome of histologically verified adult brainstem gliomas in Switzerland: a retrospective analysis of 21 patients
16.04.2014J Neurooncol 2014; 118:321-328
Hundsberger Thomas, Tonder Michaela, Hottinger Andreas, Brügge Detlef, Roelcke Ulrich, Putora Paul Martin, Stupp Roger, Weller Michael
T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein
Laurent J, Gnad-Vogt U, Stupp R, Quaratino S, Sessa C, Omlin A, Beck J, Gallerani E, Liedert B, Ongarello S, Bertrand C, Vicari M, Joffraud M, Gillessen Sommer S, Touvrey C, Speiser D. T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein. J Transl Med 2013; 11:5.
07.01.2013T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein
07.01.2013J Transl Med 2013; 11:5
Laurent Julien, Gnad-Vogt Ulrike S, Stupp Roger, Quaratino Sonia, Sessa Cristiana, Omlin Aurelius, Beck Joachim, Gallerani Elisa, Liedert Bernd, Ongarello Stefano, Bertrand Caroline, Vicari Manuela, Joffraud Magali, Gillessen Sommer Silke, Touvrey Cedric, Speiser Daniel E
A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours
Gillessen S, Speiser D, Laurent J, Kramer D, Liedert B, Mattiacci M, Omlin A, Sessa C, Beck J, Gallerani E, Gnad-Vogt U, Stupp R. A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours. Eur J Cancer 2012; 49:35-44.
20.08.2012A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours
20.08.2012Eur J Cancer 2012; 49:35-44
Gillessen Silke, Speiser Daniel E, Laurent Julien, Kramer Daniel, Liedert Bernd, Mattiacci Maria R, Omlin Aurelius, Sessa Cristiana, Beck Joachim, Gallerani Elisa, Gnad-Vogt Ulrike S, Stupp Roger
Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03)
Pesce G, Bernhard J, Kotrubczik N, D'Addario G, Pilop C, Weber D, Bodis S, Pless M, Mayer M, Cathomas R, Peters S, Klingbiel D, Ribi K, Zouhair A, von Moos R, Schlaeppi M, Caspar C, Fischer N, Anchisi S, Stupp R. Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03). Eur J Cancer 2011; 48:377-84.
15.11.2011Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03)
15.11.2011Eur J Cancer 2011; 48:377-84
Pesce Gianfranco A, Bernhard Jürg, Kotrubczik Nina M, D'Addario Giannicola, Pilop Christiane, Weber Damien C, Bodis Stephan, Pless Miklos, Mayer Michael, Cathomas Richard, Peters Solange, Klingbiel Dirk, Ribi Karin, Zouhair Abderahim, von Moos Roger, Schlaeppi Marc, Caspar Clemens B, Fischer Natalie, Anchisi Sandro, Stupp Roger
Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98
Martinelli G, Zucca E, Dietrich P, Lohri A, Vorobiof D, Heizmann M, Stahel R, Stupp R, Okkinga E, Bassi S, Hess U, Cerny T, Utiger U, Schmitz S, Ghielmini M. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol 2010; 28:4480-4.
09.08.2010Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98
09.08.2010J Clin Oncol 2010; 28:4480-4
Martinelli Giovanni, Zucca Emanuele, Dietrich Pierre-Yves, Lohri Andreas, Vorobiof Daniel, Heizmann Marc, Stahel Rolf, Stupp Roger, Okkinga Emmie, Bassi Simona, Hess Urs, Cerny Thomas, Utiger Urs, Schmitz Shu-Fang Hsu, Ghielmini Michele
Individual versus standard quality of life assessment in a phase II clinical trial in mesothelioma patients: feasibility and responsiveness to clinical changes
Ribi K, Stahel R, Ris H, Stupp R, Schmid R, Betticher D, Jörger M, Bodis S, Weder W, Schuller J, Bernhard J, Swiss Group for Clinical Cancer Research SAKK. Individual versus standard quality of life assessment in a phase II clinical trial in mesothelioma patients: feasibility and responsiveness to clinical changes. Lung cancer (Amsterdam, Netherlands) 2008; 61:398-404.
01.09.2008Individual versus standard quality of life assessment in a phase II clinical trial in mesothelioma patients: feasibility and responsiveness to clinical changes
01.09.2008Lung cancer (Amsterdam, Netherlands) 2008; 61:398-404
Ribi Karin, Stahel Rolf A, Ris Hans-Beat, Stupp Roger, Schmid Ralph A, Betticher Daniel, Jörger Markus, Bodis Stephan, Weder Walter, Schuller Jan C, Bernhard Jürg, Swiss Group for Clinical Cancer Research SAKK
Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research
Roth A, de Braud F, Seymour M, Widmer L, Glynne-Jones R, Leslie M, Wernli M, Maibach R, Rufibach K, Borner M, Köberle D, Saletti P, Bernhard J, Falk S, Stupp R, Fazio N, Swiss Group for Clinical Cancer Research. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007; 25:3217-23.
01.08.2007Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research
01.08.2007Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007; 25:3217-23
Roth Arnaud D, de Braud Filippo, Seymour Matthew, Widmer Lukas, Glynne-Jones Robert, Leslie Martin, Wernli Martin, Maibach Rudolf, Rufibach Kaspar, Borner Markus M, Köberle Dieter, Saletti Piercarlo, Bernhard Jürg, Falk Stephen, Stupp Roger, Fazio Nicola, Swiss Group for Clinical Cancer Research
Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule
Ghielmini M, Vorobiof D, Bargetzi M, Lohri A, Helg C, Kovacsovics T, Stupp R, Zucca E, Hess U, Peccatori F, Martinelli G, Betticher D, Fey M, Waltzer U, Hummerjohann J, Pichert G, Cogliatti S, Schmitz S, Cerny T. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 2004; 103:4416-23.
15.06.2004Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule
15.06.2004Blood 2004; 103:4416-23
Ghielmini Michele, Vorobiof Daniel, Bargetzi Mario, Lohri Andreas, Helg Claudine, Kovacsovics Tibor, Stupp Roger, Zucca Emanuele, Hess Urs, Peccatori Fedro, Martinelli Giovanni, Betticher Daniel C, Fey Martin F, Waltzer Ursula, Hummerjohann Jörg, Pichert Gabriella, Cogliatti Sergio B, Schmitz Shu-Fang Hsu, Cerny Thomas
Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial
Betticher D, Stahel R, Weder W, Stupp R, Egli F, Furrer M, Honegger H, Wernli M, Cerny T, Spiliopoulos A, Roth A, Hsu Schmitz S, Tötsch M, Hansen E, Joss C, von Briel C, Schmid R, Pless M, Habicht J, Ris H. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003; 21:1752-9.
01.05.2003Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial
01.05.2003Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003; 21:1752-9
Betticher Daniel C, Stahel Rolf, Weder Walter, Stupp Roger, Egli Fritz, Furrer Markus, Honegger Hanspeter, Wernli Martin, Cerny Thomas, Spiliopoulos Anastase, Roth Arnaud D, Hsu Schmitz Shu-Fang, Tötsch Martin, Hansen Eva, Joss Christine, von Briel Christian, Schmid Ralph A, Pless Miklos, Habicht James, Ris Hans-Beat